Clinical Flow Cytometry Panels Patents: Who Leads, Where the Gaps Are 2026
- 48.6% concentration. The top five assignees hold 779 of 1,604 records in scope — a field with a genuine head, not a flat field of small filers.
- 2017 was the peak. Filings hit 179 that year; the 2021→2024 span shows a -30% move (102 to 71), the last span long enough to read cleanly given publication lag.
- Composition over analysis. A61K medicinal-preparation claims cover 68.6% of records versus 24.2% for G01N analysis methods — most of the claim space is on the reagent, not the assay.
Filing growth compares 2021 (102 records) with 2024 (71) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 1,604 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Clinical flow cytometry panels sit at the intersection of reagent chemistry and diagnostic method: antibody-fluorochrome combinations, gating strategies, and the protocols that keep results consistent across laboratories. This landscape draws on 1,604 published records filed or published between 2015 and mid-2026 that combine clinical flow cytometry, immunophenotyping panel or minimal residual disease language with gating, harmonization, stability or reporting terms.
The dataset skews toward cell-therapy and oncology assignees whose panels support CAR-T and MRD monitoring rather than toward instrument or software vendors, which shapes both the IPC mix and the concentration at the top of the assignee ranking.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 1,604-record set: how filing activity has moved year over year, and which IPC subclasses carry the claims.
Filing activity peaked in 2017, then settled lower
Filings reached a peak of 179 in 2017. The 2021→2024 window — the most recent span not distorted by publication lag — moved from 102 to 71 records, a -30% change. Counts for 2025 and 2026 are still filling in and should not be read as a further decline.
Reagent and compound classes dominate over assay-method classes
A61K (medicinal preparations) appears on 68.6% of the 1,604 records and C07K (peptides & proteins) on 48.9%, reflecting how many filings are anchored to the therapeutic or antibody composition rather than the cytometry method itself. G01N (material analysis & testing), the class closest to the assay and gating workflow, covers 24.2% — a smaller but still substantial share. Because records can carry several IPC codes, these figures sum to more than 100% of the record total.
Shares are the percentage of the 1,604 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Clinical Flow Cytometry Panels with Eureka
This page is one run against one query. Ask Eureka your own question about clinical flow cytometry panels and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records and a recent filing
WO2026017800A1 — MRD panel for pediatric B-ALL
The application claims a reagent panel for detecting minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by multiparametric flow cytometry, built on a defined combination of antibodies against markers including CD45, CD20, CD34, CD38, CD10, CD58, CD66c, CD73, CD81, CD123, CD304, CD44, CD86, CD99 and CD371, together with CD19 and/or CD22, each conjugated to a fluorochrome.Filed by Medical University – Plovdiv, published 2026-01-22 — the most recent record in this dataset, illustrating how specific marker-combination claims have become in MRD panel filings.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2012079000A1 | Use of chimeric antigen receptor-modified t cells to treat cancer | 1,976 |
| 2 | US20130287748A1 | Use of Chimeric Antigen Receptor-Modified T-Cells to Treat Cancer | 1,548 |
| 3 | US8911993B2 | Compositions for treatment of cancer | 863 |
| 4 | US8906682B2 | Methods for treatment of cancer | 843 |
| 5 | US20160108458A1 | Multiplexed detection and quantification of nucleic acids in single-cells | 369 |
| 6 | US9102760B2 | Compositions for treatment of cancer | 357 |
| 7 | US8916381B1 | Methods for treatment of cancer | 353 |
| 8 | WO2016028896A1 | Anti-CD123 chimeric antigen receptor (CAR) for use in cancer treatment | 334 |
| 9 | US9102761B2 | Compositions for treatment of cancer | 332 |
| 10 | US20110212090A1 | Combinatorial Analysis and Repair | 329 |
Citation counts favour older records simply because they have had more time to accumulate citations; treat this table as a signal of influence within the searched corpus, not of which claims are currently most contested.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data tells a filing team
Three read-outs from the concentration, trend and jurisdiction figures above, translated into what they mean for a filing decision.
The field has a real head, not a flat distribution
Combined, the five leading assignees hold 779 of the 1,604 records in scope, and the ranked ten hold 972 (60.6%). That is enough concentration that a new entrant filing broad antibody-panel claims should expect to run into dense prior art from a small number of players, most tied to CAR-T and related cell-therapy programmes.
Activity has cooled from its 2017 peak but has not collapsed
The peak year was 2017 at 179 filings. The cleanest recent comparison, 2021 (102) to 2024 (71), shows a -30% move. Because publication lags filing by roughly 18 months, 2025 and 2026 figures are still incomplete and should not be read as evidence of further decline.
US filings lead, but PCT and EPO routes are close behind
The United States receives the largest single share of filings (381), with EPO (233) and WIPO/PCT (231) close together behind it. Australia, Canada and Israel each carry a meaningful but smaller share, suggesting most serious filers are pursuing multi-jurisdiction protection rather than a single home filing.
Reagent composition claims outnumber assay-method claims by a wide margin
A61K medicinal-preparation claims cover more than two-thirds of records, while G01N material-analysis claims — the class closest to the cytometry method and gating workflow itself — cover under a quarter. That gap points to where claim space is comparatively less occupied.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to clinical flow cytometry panels, with the prior art for and against each one.
Leaders, pairings and where activity has gone quiet
The ranking spans 100 assignees. Filing is concentrated among cell-therapy and academic-medical leaders, several of whom show no filings in the latest recorded year — a pattern consistent with publication lag rather than withdrawal.
A single academic assignee leads by a wide margin
The top-ranked assignee holds 355 records, more than four times the fifth-place count of 52. Its strongest co-filing pairing, with a major pharmaceutical partner, spans 148 shared records — evidence of a long-running joint CAR-T filing programme rather than isolated collaboration.
A steep drop-off after the top ten
Tenth place sits at 33 records, well below the fifth-place figure of 52 and far below the leader's 355. The top ten collectively hold 972 records (60.6% of the 1,604 in scope), leaving a long tail of single- and few-filing entrants across the remaining ranked companies.
Leading filers show no activity in the most recent recorded year
Several of the highest-ranked assignees, including the top academic filer and multiple pharmaceutical partners, show zero filings and a -100% year-on-year change in the latest year. Given the roughly 18-month publication lag, this is more likely an artefact of recent filings not yet appearing than a genuine stop in activity.
| Assignee | Recent year | YoY |
|---|---|---|
| The Trustees of the University of Pennsylvania | 0 | -100% |
| Novartis AG | 0 | — |
| The Children's Hospital of Philadelphia | 0 | -100% |
| Celgene Corp | 0 | -100% |
| Regeneron Pharmaceuticals Inc | 0 | — |
| INPROTHER APS | 0 | -100% |
| Becton, Dickinson and Company | 0 | -100% |
| Kymab Limited | 0 | -100% |
Where to take this analysis
The figures above establish where claims sit today. Two follow-on questions matter for a filing or freedom-to-operate decision.
Test a draft claim against the top assignees' portfolios
With 48.6% of records held by five assignees, a new panel or method claim should be checked directly against their filings before drafting proceeds further.
Explore assignee portfolios in EurekaProbe the under-claimed gating and harmonization branches
G01N-class claims sit well below A61K claims by share of records, suggesting assay-method and workflow claims have more open ground than composition claims.
Run a white-space search in EurekaCommon questions on this landscape
Filing is concentrated: the leading assignee alone holds 355 of the 1,604 records in scope, and the top five combined hold 779 records (48.6%). Most of this concentration traces to academic-medical centres and pharmaceutical companies working on CAR-T and related cell-therapy programmes, where flow cytometry panels are used for immunophenotyping and minimal residual disease monitoring. Below the top ten, filing activity spreads across a long tail of assignees with far fewer records each, so a full freedom-to-operate check needs to look well past the leaders.
Filings peaked in 2017 at 179 records and have since settled lower. The most reliable recent comparison, 2021 to 2024, shows a -30% change (102 down to 71 records), and 2024 is the most recent year that can be treated as reasonably complete. Figures for 2025 and 2026 are still incomplete because publication typically lags filing by around 18 months, so they should not yet be read as confirming a continued decline.
WO2026017800A1, filed by Medical University – Plovdiv and published in January 2026, claims a reagent panel for detecting minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia using multiparametric flow cytometry. The claimed panel specifies a defined combination of fluorochrome-conjugated antibodies against a named set of markers including CD45, CD34, CD38, CD10 and CD371, alongside CD19 and/or CD22. Anyone building a similar pediatric B-ALL MRD panel with an overlapping marker combination and conjugation scheme should review this filing's exact claim scope before finalising a panel design.
A61K (medicinal preparations) appears on 68.6% of the 1,604 records and C07K (peptides & proteins) on 48.9%, showing that most filings anchor their claims to the reagent or antibody composition. G01N (material analysis & testing), the class closest to the cytometry assay and gating method itself, covers a smaller 24.2% share. That gap is useful context for drafting: composition claims face denser prior art than method-of-analysis claims in this dataset.
Relative to the dense composition claims covering reagents and antibody panels, method-oriented branches such as interlaboratory gating reproducibility, automated panel harmonization, sample stability protocols and standardized MRD reporting templates show comparatively lower filing density in this dataset. These are not confirmed as open, only as less crowded by the classes and records examined here, so a targeted prior-art search on the specific claim language is still necessary before filing.
Research Clinical Flow Cytometry Panels in depth with Eureka
Go past this page: query the whole clinical flow cytometry panels corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.